UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 23, 2017
Anika Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
____________________
| Massachusetts | 000-21326 | 04-3145961 |
| (State or other jurisdiction of | Commission file number | (I.R.S. Employer |
| incorporation or organization) | | Identification No.) |
32 Wiggins Avenue, Bedford, MA 01730
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code:781-457-9000
(Former name or former address, if changed since last report)
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[_]Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_]Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[_]Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_]Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 5—Corporate Governance and Management
Item 5.02. Departure of Certain Officers.
Effective January 23, 2017, the employment of Stephen R. Mascioli, M.D., MPH, as Chief Medical Officer of Anika Therapeutics, Inc. has ended.
[Remainder of page left blank intentionally]
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be filed on its behalf by the undersigned hereunto duly authorized.
| | Anika Therapeutics, Inc. | |
| | | | |
| | | | |
| Dated: January 27, 2017 | By: | /s/ Sylvia Cheung | |
| | | Sylvia Cheung | |
| | | Chief Financial Officer |
